- Curadev Pharma
Curadev Pharma was founded in 2010 by a team of professionals from the pharmaceutical and biotech sectors with the mission to enhance the quality of human life by accelerating the discovery and delivery of new drugs.
Curadev Pharma develops and monetises intellectual property (IP) and they out-license their IP to partner organisations with strong clinical development programmes. Their focus is the discovery and development of new chemical entities (NCEs) against specific therapeutic target and the discovery and development of novel drug delivery vehicles.
Curadev Pharma has recently won a contract from Roche worth close to $555m to develop immuno-oncology drugs.
Curadev has been working with academics in the UK since 2011 and our subsidiary Curadev Pharma Ltd, UK, created this year, was a natural progression that expanded our footprint. Curadev’s entry into Europe is augmented by the recognition conferred by IE20.
Manish Tandon, CFO, Curadev Pharma
> Back to India's Emerging Twenty